Avalo Therapeutics Inc
General ticker "AVTX" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $59.5M
Avalo Therapeutics Inc follows the US Stock Market performance with the rate: 18.6%.
Estimated limits based on current volatility of 5.5%: low 8.45$, high 9.44$
Factors to consider:
- Current price 13.3% below estimated low
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [10.16$, 31.48$]
- 2024-12-30 to 2025-12-30 estimated range: [6.86$, 17.81$]
Financial Metrics affecting the AVTX estimates:
- Negative: Non-GAAP EPS, $ of -485.26 <= 0.10
- Negative: Operating profit margin, % of -92.42 <= 1.03
- Negative: Operating cash flow per share per price, % of -88.53 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -23.87 <= 3.85
- Negative: Industry operating profit margin (median), % of -98.30 <= 2.14
Short-term AVTX quotes
Long-term AVTX plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $5.40MM | $18.05MM | $1.92MM |
Operating Expenses | $87.53MM | $55.49MM | $25.37MM |
Operating Income | $-82.13MM | $-37.44MM | $-23.44MM |
Non-Operating Income | $-2.41MM | $-4.19MM | $-8.09MM |
Interest Expense | $2.39MM | $4.17MM | $3.42MM |
R&D Expense | $59.84MM | $31.31MM | $13.78MM |
Income(Loss) | $-84.55MM | $-41.63MM | $-31.53MM |
Taxes | $-0.20MM | $0.03MM | $0.01MM |
Other Income(Loss) | $-0.03MM | $0.00MM | $0.00MM |
Profit(Loss) | $-84.38MM | $-41.66MM | $-31.54MM |
Stockholders Equity | $23.08MM | $-10.91MM | $7.30MM |
Inventory | $0.04MM | $0.02MM | $0.00MM |
Assets | $80.21MM | $33.37MM | $20.99MM |
Operating Cash Flow | $-70.89MM | $-26.75MM | $-30.68MM |
Capital expenditure | $0.11MM | $0.10MM | $0.16MM |
Investing Cash Flow | $-0.11MM | $-0.10MM | $-0.13MM |
Financing Cash Flow | $106.76MM | $-14.70MM | $25.04MM |
Earnings Per Share* | $-2,330.66 | $-1,062.65 | $-113.58 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.